Cortavance cutaneous spray for dogs 76 ml
Treatment of inflammatory and pruritic dermatoses in dogs
CORTAVANCE 0.584 mg/ml cutaneous spray solution for dogs
2. QUALITATIVE AND QUANTITATIVE COMPOSITION OF CORTAVANCE 0.584 mg/ml
Hydrocortisone aceponate 0.584 mg/ml.
For a full list of excipients see section 6.1.
3. PHARMACEUTICAL FORM OF CORTAVANCE 0.584 mg/ml
Cutaneous spray, solution.
4. CLINICAL PARTICULARS OF CORTAVANCE 0.584 mg/ml
4.1 Target species
4.2 Indications for use, specifying the target species
For symptomatic treatment of inflammatory and pruritic dermatoses in dogs.
Do not use on cutaneous ulcers.
4.4 Special warnings for each target species
Total body surface treated should not exceed a surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs. Otherwise, use only according to the risk-benefit assessment and subject the dog to regular clinical evaluations.
4.5 Special precautions for use
Special precautions for use in animals
In the case of concurrent microbial disease or parasitic infestation, the dog should receive appropriate treatment for such condition.
In the absence of specific information, the use in animal suffering from Cushing’s syndrome shall be based on the risk-benefit assessment.
Since glucocorticosteroids are known to slow growth, use in young animals (under 7 months of age) shall be based on the risk-benefit assessment and subject to regular clinical evaluations.
In 12 dogs suffering from atopic dermatitis, after topical application on the skin at the recommended therapeutic dosage for 28 to 70 consecutive days, no noticeable effect on the systemic cortisol level was observed.
Special precautions to be taken by the person administering the veterinary medicinal product to animals
In case of accidental skin contact, it is recommended to wash thoroughly with water. Wash hands after use.
Avoid contact with eyes. In case of accidental eye contact, rinse with abundant quantities of water. In case of eye irritation, seek medical advice.
In case of accidental ingestion, seek medical advice immediately and show the leaflet or the label to the physician.
Spray preferably in a well ventilated area.
Do not spray on naked flame or any incandescent material. Do not smoke while handling the veterinary medicinal product.
The solvent in this product may stain certain materials including painted, varnished or other household surfaces or furnishings. Allow the application site to dry before permitting contact with such materials.
4.6 Adverse reactions (frequency and seriousness)
Transient local reactions at the application site (erythema and/or pruritus) can occur in very rare cases (less than 1 in 10,000 animals).
4.7 Use during pregnancy, lactation or lay
The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Systemic absorption of hydrocortisone aceponate being negligible, it is unlikely for teratogenic, foetotoxic, maternotoxic effects to happen at the recommended dosage in dogs.
Use only accordingly to the risk-benefit assessment by the responsible veterinarian.
4.8 Interaction with other medicinal products and other forms of interaction
In the absence of information, it is recommended not to apply other topical preparations simultaneously on the same lesions.
4.9 Amounts to be administered and administration route
Before administration, screw the pump spray on the bottle.
The veterinary medicinal product is then applied by activating the pump spray, from a distance of about 10 cm of the area to be treated.
The recommended dosage is 1.52 µg of hydrocortisone aceponate/cm2 of affected skin per day. This dosage can be achieved with two pump spray activations over a surface to be treated equivalent to a square of 10 cm x 10 cm. Repeat the treatment daily for 7 consecutive days.
Care should be taken to avoid spraying into the eyes of the animal.
Presented as a volatile spray, this veterinary medicinal product does not require any massage.
In case of conditions requiring an extended treatment, the responsible veterinarian should subject the use of the veterinary medicinal product to the risk-benefit assessment.
If signs fail to improve within 7 days, treatment should be re-evaluated by the veterinarian.
4.10 Overdose (symptoms, emergency procedures, antidotes)
After topical application on the skin at the recommended therapeutic dosage and twice the recommended duration of treatment and at up to a body surface corresponding to the two flanks, from the spine to the mammary chains including the shoulder and the thighs, no systemic effects are observed.
Tolerance studies using 3 and 5 times the recommended dosage for twice the recommended duration of treatment resulted in a reduced capacity for production of cortisol that is fully reversible within 7 to 9 weeks after the end of treatment.
4.11 Withdrawal periods
5. PHARMACOLOGICAL PROPERTIES OF CORTAVANCE 0.584 mg/ml
Pharmacotherapeutic group: Glucorticosteroids, dermatological preparations. ATCvet code: QD07AC.
5.1 Pharmacodynamic properties
The veterinary medicinal product contains the active substance hydrocortisone aceponate.
Hydrocortisone aceponate is a dermocorticoid with a potent intrinsic glucocorticoid activity which means a relief of both inflammation and pruritus leading to a quick improvement of skin lesions observed in case of inflammatory and pruritic dermatosis.
5.2 Pharmacokinetic particulars
Hydrocortisone aceponate belongs to the diesters class of the glucocorticosteroids.
The diesters are lipophilic components ensuring an enhanced penetration into the skin associated to a low plasma availability. Hydrocortisone aceponate thus accumulates in the dog’s skin allowing local efficacy at low dosage. The diesters are transformed inside the skin structures. This transformation is responsible for the potency of the therapeutic class. In laboratory animals, hydrocortisone aceponate is eliminated the same way as hydrocortisone (other name for endogenous cortisol) through urine and faeces.
Topical application of diesters results in high therapeutic index: high local activity with reduced systemic secondary effects.
6. PHARMACEUTICAL PARTICULARS OF CORTAVANCE 0.584 mg/ml
6.1 List of excipients
Propylene glycol methyl ether.
6.3 Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale: 2 years. Shelf-life after first opening the immediate packaging: 6 months.
6.4. Special precautions for storage
This veterinary medicinal product does not require any special storage conditions.